Acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors
Arco Lab now holds a 50% stake in Neviton
Comprehensive clinical development programs being initiated for each investigational candidate
The company has received five final approvals
The company received gross proceeds of approximately US$1.7 million and net proceeds,
Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes
The establishment of the facility demonstrates the company's commitment to delivering differentiated solutions to gynecology and pediatrics challenges
Transaction delivers KarXT, a first-in-class M1/ M4 muscarinic receptor agonist with differentiated efficacy and safety
Subscribe To Our Newsletter & Stay Updated
